Clinical laboratories remain one of the most indispensable parts of the healthcare system. Doctors rely on lab results to inform, adjust, and justify clinical decisions. Yet across the UK and Europe, the pressures on pathology services are ever increasing with staffing shortages, increasing test volumes, and persistent cost containment measures are threatening both speed and quality of diagnostic workflows.

Against this backdrop, the NGX 124, set for release in October 2025 across the United Kingdom and European Union, offers a timely and transformative solution.

Evidence of Systemic Strain

The urgency of innovation is clear described in a survey conducted by Siemens Healthineers and YouGov which found that 99 percent of physicians agree clinical lab testing is integral to patient care, and 96 percent warned that staffing shortages in laboratories are already undermining outcomes. As one physician respondent put it, “Lab tests help determine my actions by providing crucial clarity in uncertain cases.”

Physicians also highlighted how laboratory insights streamline the use of other healthcare resources, reducing unnecessary interventions. Yet financial pressures and workforce shortages continue to erode capacity.

The NGX 124 directly addresses these pain points:

• Automation helps overcome workforce shortages
• Scalable design supports rapid assay adoption without additional infrastructure
• Lower cost per result aligns with budget conscious health systems

 Why the NGX 124 matters

The NGX 124 is a high throughput, open format molecular diagnostics platform designed to help laboratories:

• Increase throughput without increasing headcount
• Automate repetitive workflows while retaining flexibility for laboratory developed tests (LDTs)
• Reduce per test cost by optimising reagent usage and instrument uptime
• Shorten turnaround times, improving downstream decision making for clinicians

In short: more results, lower cost, fewer bottlenecks.

By integrating NGX 124 into routine operations, pathology teams can reallocate staff time away from manual tasks, reduce overtime expenditure, and meet growing clinical demand without sacrificing accuracy or responsiveness. For overstretched systems, this is not a luxury, it is a necessity.

Be an Early Adopter

To ensure quality control and maximise early stage support, only nine pre-production NGX 124 platforms will be made available for placement across the UK and Western Europe from launch through December 2025.

• Early adopter placements are extremely limited.
• Each platform will be deployed with close technical support, data sharing agreements, and preferential pricing for future units.
• Sites selected for early placement will shape the evidence base, influence protocol development, and secure operational advantage ahead of wider commercial rollout in 2026.

Laboratories wishing to modernise their molecular testing infrastructure and reduce both direct and indirect costs are strongly encouraged to register interest early. Once the first nine placements are allocated, the next opportunity will not come until the full scale commercial launch in 2026.

Summary

The NGX 124 is more than a new instrument, it is an enabling technology for the future of decentralised, efficient, and sustainable diagnostics. For laboratories seeking to do more with less, it represents an opportunity to lead, not follow.

Expressions of interest for early placement are now open.
Sites will be selected based on technical readiness, volume potential, and alignment with our early adopter programme.